US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

27.37

+0.01270.05%

Post-market: 27.500.1304+0.48%16:10 EDT

Volume:1K

Turnover:32.81K

Market Cap:2.46M

PE:- -

High:27.50

Open:27.40

Low:27.37

Close:27.36

52wk High:28.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:3.97

T/O Rate:1.33%

Dividend:0.45

Dividend Rate:1.65%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Pharming wins FDA nod to extend Joenja use to younger APDS children

The Race for the Next Big Weight-Loss Drug is On-and China Wants In

Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding

Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

ProQR Therapeutics doses first participant in AX-0811 clinical trial

Bayer initiates Phase II study of BAY 3670549 in patients with AFib

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

Tech Giant Pours Record €13 Billion into Nordic AI Hub

Evotec initiates clinical trial evaluating JST-018

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Medicus Pharma Sharpened Strategy Centers on Precision Oncology and Targeted Rare Disease Programs

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Ascletis Starts U.S. Phase I Trial of Oral Obesity Drug ASC36

Roivant Sciences announces ‘positive’ results from Phase 2 PHocus clinical trial

MediciNova to Participate in Two Investor Conferences in September

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/NVIB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":27.3696,"timestamp":1789156800000,"preClose":27.3569,"halted":0,"volume":1193,"hourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"delay":0,"changeRate":0.000464233886149338,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Market Closed","change":0.0127,"latestTime":"09-11 16:00:00 EDT","open":27.401,"high":27.5,"low":27.3696,"amount":32812,"amplitude":0.004767,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":27.3569,"nav":27.337,"aum":2460334.39,"dividendRate":0.016467,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"volumeRatio":3.974015203722743},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.974015203722743,"shares":90001,"dividePrice":0.4507,"high":27.5,"amplitude":0.004767,"preClose":27.3569,"low":27.3696,"week52Low":24.54,"pbRate":"--","week52High":28.8896,"institutionHeld":0,"latestPrice":27.3696,"eps":0,"divideRate":0.016467,"volume":1193,"delay":0,"ttmEps":0,"open":27.401,"prevYearClose":25,"prevWeekClose":28.8896,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":28.4889,"twentyDayClose":28.3265},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666795715","title":"Pharming wins FDA nod to extend Joenja use to younger APDS children","url":"https://stock-news.laohu8.com/highlight/detail?id=2666795715","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666795715?lang=en_us&edition=fundamental","pubTime":"2026-09-12 02:32","pubTimestamp":1789151567,"startTime":"0","endTime":"0","summary":"Pharming Group ( ($NL:PHARM) ) has provided an announcement. Pharming has secured U.S. FDA approval for new 40 mg and 50 mg twice-daily doses of Jo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","MEDI","RSPH","IEIH","LFSC","IDNA","SYNB","MRNX","GDOC","NVIB","TECB","IBB","FRTY","LABU","BMED","BK4588","XLVX","IYH","PSCH","BBP","BK4585","MRNY","TBXU","PINK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666111665","title":"The Race for the Next Big Weight-Loss Drug is On-and China Wants In","url":"https://stock-news.laohu8.com/highlight/detail?id=2666111665","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666111665?lang=en_us&edition=fundamental","pubTime":"2026-09-11 08:00","pubTimestamp":1789084800,"startTime":"0","endTime":"0","summary":"SHANGHAI-Chinese biotech companies, rapidly evolving from manufacturers of low-end generic drugs to serious competitors to American pharma giants, are training their sights on one of the most lucrativ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","BMED","GDOC","XBIX","JDOC","IDNA","NVIB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666518847","title":"Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2666518847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666518847?lang=en_us&edition=fundamental","pubTime":"2026-09-11 02:21","pubTimestamp":1789064460,"startTime":"0","endTime":"0","summary":"Investors poured fresh capital into applied AI and precision biotech this week, with Gimlet Labs raising $300M at a $3B valuation and Encoded Thera...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/private-markets-gimlet-labs-encoded-therapeutics-secure-new-funding-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/private-markets-gimlet-labs-encoded-therapeutics-secure-new-funding-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","CHAT","TSPA","NVIB","VTHR","AGIX","BK4539","TACU","QTOC","LENZ","AIPO","XBIX","CDIG","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666910405","title":"Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2666910405","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666910405?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:25","pubTimestamp":1789050337,"startTime":"0","endTime":"0","summary":"Optimi Health (OPTH) announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with maj...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","BK4139","PSIL","GDOC","MEDX","NVIB","BK4007","OPTH","ABVC","HYLG","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666599595","title":"IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2666599595","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666599595?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:30","pubTimestamp":1789047000,"startTime":"0","endTime":"0","summary":"Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens IMUNON retains ownership of its background intellectual property wit","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359640/0/en/imunon-enters-cooperative-research-and-development-agreement-with-national-cancer-institute-to-advance-clinical-development-of-imnn-001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","BK4139","NCI","NHLD","IDNA","MEDX","GDOC","HYLG","IMNN","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598627","title":"CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598627","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598627?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:33","pubTimestamp":1789039980,"startTime":"0","endTime":"0","summary":"Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359400/0/en/camp4-therapeutics-receives-authorization-in-the-united-kingdom-for-phase-1-2-human-clinical-trial-of-cmp-002-in-patients-with-syngap1-related-disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4200","BK4139","CMP","NVIB","BK4007","MEDX","UBCP","BK4211","LENZ","ASO","BK4561","HYLG","IDNA","BK4168","GDOC","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666907533","title":"IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666907533","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666907533?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:30","pubTimestamp":1788957000,"startTime":"0","endTime":"0","summary":"Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept.  09, 2026 (GLOBE NEWS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358657/0/en/imunon-announces-full-agenda-and-speaker-lineup-ahead-of-2026-r-d-day-highlighting-imnn-001-clinical-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","IMNN","MEDX","GDOC","BK4097","IDNA","HYLG","NVIB","PRGS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538091","title":"ProQR Therapeutics doses first participant in AX-0811 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538091?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:15","pubTimestamp":1788956125,"startTime":"0","endTime":"0","summary":"ProQR Therapeutics (PRQR) announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. Publi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","AX","LENZ","LU1861217088.USD","BK4007","BK4211","BK4195","BK4139","LU2360107671.USD","MEDX","NVIB","PRQR","BK4539","GDOC","LU1861220207.SGD","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538313","title":"Bayer initiates Phase II study of BAY 3670549 in patients with AFib","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538313","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538313?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:45","pubTimestamp":1788954315,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced the initiation of a global Phase II clinical trial evaluating BAY 3670549, an investigational highly selective G-protein-co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-initiates-phase-ii-study-of-bay-3670549-in-patients-with-afib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-initiates-phase-ii-study-of-bay-3670549-in-patients-with-afib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BAY","BAYRY","GDOC","HYLG","MEDX","NVIB","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666858794","title":"Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666858794","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666858794?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358477/24675/en/fate-therapeutics-announces-encore-clinical-data-presentation-of-ft819-off-the-shelf-car-t-cell-product-candidate-at-the-ccr-west-2026-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","IDNA","GDOC","MEDX","BK4139","HYLG","BK4077","NVIB","CCR","BMED","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587949","title":"Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587949","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587949?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358458/0/en/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-trial-of-opgx-best1-and-successful-fda-type-c-meeting-with-potential-phase-3-dosing-in-2027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARB","GDOC","HYLG","BK4585","MEDX","BK4588","NVIB","LABU","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666558799","title":"Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247","url":"https://stock-news.laohu8.com/highlight/detail?id=2666558799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666558799?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle d","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358479/0/en/satellos-announces-forazapadin-as-assigned-international-nonproprietary-name-for-lead-drug-candidate-sat-3247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","GDOC","INN","MEDX","BK4218","IDNA","BK4181","HYLG","SAT","NVIB","DBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155106466","title":"Tech Giant Pours Record €13 Billion into Nordic AI Hub","url":"https://stock-news.laohu8.com/highlight/detail?id=1155106466","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155106466?lang=en_us&edition=fundamental","pubTime":"2026-09-09 17:25","pubTimestamp":1788945959,"startTime":"0","endTime":"0","summary":"Search engine behemoth Alphabet is making its largest-ever European commitment, funneling €13 billion (approximately $15.1 billion USD) into Finnish artificial intelligence infrastructure. This...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGOOGmain","LU1119994496.HKD","HK0000304797.USD","LU0690374961.EUR","LU1400636491.USD","SG9999014542.SGD","LU2237443622.USD","LU0472753341.HKD","LU2028103732.USD","FXL","LU0345774631.USD","LU0096362180.USD","AXTC","LU1674673691.USD","GB00B4QBRK32.GBP","LU1496350502.SGD","LU2491049909.HKD","LU1066053197.SGD","IE00BMPRXN33.USD","LU2458330243.SGD","LU0251132253.USD","LU1935042215.USD","LU0061474960.USD","ORAC","AVL","LU2191332357.HKD","LU0795875086.SGD","BK4579","SG9999017495.SGD","LU2357627491.SGD","LU0094547139.USD","LU2404859741.USD","LU1144417596.USD","LU0889565833.HKD","LU2456880835.USD","LU0964807845.USD","LU1035775433.USD","AMZP","LU0211326839.USD","LU0251131958.USD","IE00B5949003.HKD","LU0689626769.HKD","LU1823568750.SGD","IE0034235295.USD","LU0056508442.USD","IE00BHPRN162.USD","LU0342679015.USD","LU1670627923.USD","LU0823434740.USD","GOOX","CMAG","LU0312595415.SGD","LU0426417589.USD","LU2237443549.SGD","ILDR","LU2271345857.HKD","RSPT","LU0784385170.HKD","LU1232071149.USD","SG9999000418.SGD","LU1267930490.SGD","BK4527","LU0689472784.USD","LU2087621335.USD","LU2471134879.HKD","AVGU","LU1923622614.USD","LU1064131342.USD","LU1880398554.USD","LU2065171402.SGD","ORCS","LU0868494617.USD","LU2360106780.USD","LU2491050071.SGD","SG9999014880.SGD","TTXU","LU0079474960.USD","LU1934455863.HKD","BTHM","CRTC","LU2168564065.EUR","LU0128525689.USD","GOOP","LU0640476718.USD","BK4533","LU2097829019.USD","LU2023250504.SGD","SMCC","FDIF","IE00B19Z8X17.USD","LU0323591593.USD","IE00B3S45H60.SGD","AMZU","LU0302445910.USD","FRWD","BK4585","DAT","INVN","LU0265550946.USD","LU2092937148.SGD","LU0788109477.HKD","HK0000819398.USD","IE00BLSP4239.USD","LU0912757837.SGD","LU0965509010.AUD","LU0943347566.SGD","LU2098885051.SGD","LU2092627202.USD","BK4576","SGXZ44715902.SGD","SG9999018857.SGD","LU1267930730.SGD","LU2505996509.AUD","LU0353189763.USD","TIME","XQQI","SPRX","LU0708994859.HKD","LU0980610538.SGD","LU0211327993.USD","LU0648000940.SGD","LU1839511570.USD","AXTQ","LU0211328371.USD","LU0949170772.SGD","LU1803068623.USD","LU0724617625.USD","LU1894683264.USD","IE00B19Z8W00.USD","IE00B775H168.HKD","IE00BN8TJ469.HKD","LU0878866978.SGD","SG9999002232.USD","LU2247934214.USD","LU2756315664.SGD","IE00BSNM7G36.USD","LU0444973449.USD","LU0784383803.USD","LU1121112475.USD","LU2362540622.SGD","LU1718418525.SGD","IE00BQXX3F31.USD","AIQD","IE00BYXW3230.USD","LU2125154778.USD","LU2452424414.USD","LU0006306889.USD","SMYY","LU0130102774.USD","LU1791710582.SGD","LU1323610961.USD","LU0476273544.USD","LU2237443382.USD","LU0048573561.USD","LU2602419157.SGD","LU2403377893.USD","LU0417517546.SGD","LU1145028129.USD","IE00BD6J9T35.USD","LU0310799852.SGD","LU0823421333.USD","LU1221951046.USD","LU1629891620.HKD","SG9999014898.SGD","AIVC","LU0128525929.USD","LU0130103400.USD","LU1670756490.USD","LU1720051017.SGD","LU2237443978.SGD","LU1551013342.USD","IE00BK4W5M84.HKD","SG9999015341.SGD","LU0070217475.USD","SG9999015978.USD","LU1116320901.HKD","AVGW","NTAL","LU2543165471.USD","LU0256863902.USD","LU1571399168.USD","LU0256863811.USD","BK4587","LU1670628061.USD","LU1674673428.USD","LU0456855351.SGD","LU2720916845.USD","LU0494093205.USD","LU0957808578.USD","IE00BYQQ9H92.USD","LU2362541273.HKD","LU1201861249.SGD","LU1642822529.SGD","LU0823421416.USD","LU1435385759.SGD","LU1720051108.HKD","LU2089283258.USD","EFIV","LU0354030511.USD","LU2430703178.SGD","LU0124676726.USD","IE00BQXX3C00.GBP","LU2168563687.JPY","IE000SO60NU8.SGD","LU1935042991.SGD","LU0069063385.USD","LU0133085943.USD","LU1267930573.SGD","LU2213496289.HKD","LU0070302665.USD","LU0072462426.USD","IE00BKPKM429.USD","LU0211331839.USD","BK4554","LU1804176565.USD","LU0068578508.USD","TEK","LU2244417387.USD","GOGL","GOU","QQQG","IE00BN29S564.USD","LU0138981039.USD","LU2242650005.HKD","IE0005OL40V9.USD","IE00BDRTCR15.USD","BK4553","LU1221951129.SGD","LU0267386448.USD","LU2491050154.USD","LU2552382058.USD","LU2361045086.USD","IE0001KFT4U8.USD","LU2237443895.HKD","LU1868837300.USD","LU2433249047.HKD","LU2347655156.SGD","LU0882574139.USD","IE0004086264.USD","IE00BJJMRX11.SGD","LU2168564222.USD","LU2133065610.SGD","LU0158827781.USD","LU2361044949.HKD","GB00B4LPDJ14.GBP","LU2552382132.HKD","LU0859254822.USD","IE0004091025.USD","SG9999014575.USD","LU0310800379.SGD","LU1066051498.USD","LU2111349929.HKD","LU1066051811.HKD","LU0965509101.SGD","LU1691799644.USD","LU2087625088.SGD","IE0009356076.USD","LU2361044865.SGD","LU1732799900.SGD","LU0320765059.SGD","BK4574","LTL","IE00BZ1G4Q59.USD","SG9999015358.SGD","LU1551013425.SGD","ORCX","QMNV","LU0345774391.USD","AXTX","LU1153585028.USD","IE0004445239.USD","WDCC","LU0158827948.USD","LU1585245621.USD","LU1400636657.SGD","LU0052756011.USD","LU1791710400.SGD","LU0211326755.USD","LU0784384876.USD","LU2750360641.GBP","LU2458330169.SGD","LU1914381329.SGD","LU0154236417.USD","LU1069344957.HKD","LU2063271972.USD","LU1935043452.HKD","LU2417539215.USD","LU1868836914.USD","IE00B19Z3B42.SGD","LU0444971666.USD","LU2750360997.AUD","LU0210528500.USD","LU0792757196.USD","HK0000914686.HKD","LU1059921491.USD","LU0077335932.USD","LU1645745479.HKD","LU2592432038.USD","LU0203345920.USD","LU1852331112.SGD","LU2471134523.USD","BAY","LU0985489474.SGD","GOOGL","LU1244550577.SGD","LU0726765562.USD","LU0820561818.USD","BK4592","LU0648001328.SGD","SG9999014914.USD","LU1974910355.USD","LU2097344431.USD","IE00BKVL7J92.USD","LU2430703095.HKD","LU2404859667.USD","SGXZ81514606.USD","LU1989764748.USD","HK0000304805.HKD","LU0011850046.USD","LU0942090050.USD","LU0314106906.USD","AZYY","LU0203201768.USD","LU2168564149.EUR","LU0965508806.USD","LU1548497426.USD","LU1815336760.USD","LU0251142724.SGD","LU0029864427.USD","LU0238689110.USD","LU0109392836.USD","AMZW","QXQ","LU1489326972.SGD","SMCZ","LU2054465674.USD","AVGC","LU0661504455.SGD","LU1917777945.USD","LU0130517989.USD","LU2860962120.EUR","IE000WAW04H5.SGD","LU1951200564.SGD","LU1868837136.USD","LU0786609619.USD","LU0265550359.USD","LU0642271901.SGD","LU2065171311.SGD","LU2250418816.HKD","LU0276348264.USD","LU0683600562.USD","USJW.SI","LU1366192091.USD","AIS","LU2102340556.USD","LU2999663052.SGD","LU0795875169.SGD","QQJG","LU1035773651.USD","LU0861579265.USD","LU1400636574.HKD","LU0345769128.USD","LU2089284900.SGD","LU2462591277.SGD","LU1267930227.SGD","IE00BJLML261.HKD","IE0000B7K699.USD","LU0553294199.USD","BK4525","LU0210533765.USD","LU0672654240.SGD","LU1951198990.SGD","SGXZ99366536.SGD","LU1934455194.USD","SG9999015986.USD","SMCX","BK4538","LU0820562030.AUD","LU0742534661.SGD","IE00B1XK9C88.USD","LU0820561909.HKD","LU2430703251.USD","IE00B19Z9505.USD","BK4532","LU0061474705.USD","LU1235294995.USD","LU0109391861.USD","LU0345770993.USD","LU0187121727.USD","LU1046421795.USD","LU1935042488.USD","LU0289941410.SGD","SG9999014559.SGD","LU1732800096.USD","LU1196500208.SGD","AMZZ","LU1923623000.USD","NVIB","LU0106261372.USD","LU2347655073.USD","SG9999014567.USD","LU1935043536.SGD","LU0215105999.USD","LU0395794307.EUR","IE000M9KFDE8.USD","LU2077746001.SGD","IE00BBT3K403.USD","IE00B1BXHZ80.USD","LU0289961442.SGD","LU1778281490.HKD","LU2461242641.AUD","BK4581","IE0002270589.USD","IE00B7KXQ091.USD","LU2168564495.EUR","LU0345769631.USD","LU0354030438.USD","LU0345770308.USD","IE00BK4W5L77.USD","LU0289739343.SGD","LU1032955483.USD","LU2237443465.HKD","GOOL","BK4602","IE0034235188.USD","LU2065170008.USD","IE00BFSS7M15.SGD","IE00B775SV38.USD","AMZG","LU2023250330.USD","QNXT","IE00B7SZLL34.SGD","LU1043141396.HKD","LU2463028550.USD","LU1989764664.SGD","SG9999014906.USD","FCOM","SG9999015945.SGD","LU0965509283.SGD","LU0708995401.HKD","LU1116320737.USD","IE0034235303.USD","LU2275660780.HKD","WDAI","LU0097036916.USD","LU0316494557.USD","AMAA","BK4566","TRUC","LU1066051225.USD","LU2125154935.USD","LU0889566641.SGD","LU2023250843.SGD","LU2471134796.USD","LU1303367103.USD","BK4548","EPAI","IE00BWXC8680.SGD","LU0174119429.USD","LU1989772923.USD","IE00B19Z3581.USD","LU2242649171.HKD","LU2896262040.SGD","SG9999002224.SGD","IE00BQXX3D17.EUR","LU0784385840.USD","LU2462591350.SGD","IE00BJJMRY28.SGD","LU2065169927.USD","LU0048584097.USD","LU2326559502.SGD","LU0957791311.USD","LU1868836591.USD","BK4561","ORCZ","LU2552382215.SGD","IE00B5TLWC47.USD","LU1868836757.USD","LU0738911758.USD","LU1803068979.SGD","LU2097344357.USD","LU2357305700.SGD","QBIG","LU2264538146.SGD","BK4503","LU0320765489.SGD","AXTU","DRAI","LU0175139822.USD","LU0203347892.USD","LU1037948541.HKD","LU1037948897.HKD","LU2125909593.SGD","LU1202635105.USD","HK0000914660.USD","LU0477156953.USD","LU1894683348.USD","LU1633808545.USD","LU2764263039.SGD","WDCX","LU0127658192.USD","LU0985320562.USD","LU1127390331.HKD","GTEK","LU0157215616.USD","LU0170899867.USD","IE000MB6IJN5.SGD","LU2211815571.USD","LU2471134952.CNY","LU0234570918.USD","LU2505996681.GBP","SGXZ31699556.SGD","AVGX","LU2106854487.HKD","LU0496365809.HKD","LU1496350171.SGD","GOOW","LU2954938101.SGD","LU0466842654.USD","BK4612","XDAT","IVEP","LU2462157665.USD","TEKY","LU2746668461.USD","LU0053666078.USD","LU1506573853.SGD","LU1814569148.SGD","LU0080751232.USD","LU0976567544.SGD","LU1316542783.SGD","BK4588","LU0823434583.USD","LU1267930813.SGD","OGIG","LU1935043023.USD","IE00BFXG0V08.USD","SG9999018865.SGD","LU2756315318.SGD","BK4573","LU0426412945.USD","LU2746668974.SGD","LU0082616367.USD","LU0690374615.EUR","LU2286300806.USD","LU1244550221.USD","LU0210536198.USD","LU0528227936.USD","CQTM","LU0198837287.USD","LU1989772840.SGD","XLKI","VOX","LU2764263203.CNY","LU1880398471.USD","BK4514","LU0208291251.USD","LU0162691827.USD","LU1261432733.SGD","GGLS","AGIQ","IE00BFSS8Q28.SGD","LU1815333072.USD","IE00BJTD4V19.USD","AMZY","IE000F7OJYX1.SGD","LU2487616109.SGD","GXPC","LU0477156797.USD","LU0203202063.USD","LU0308772762.SGD","LU1043141123.HKD","SGXZ51526630.SGD","IE00B4JS1V06.HKD","BK4550","JGRO","LU0072461881.USD","LU0310800965.SGD","AIPI","IE00BKDWB100.SGD","LU0107464264.USD","LU2420271590.USD","ALAI","LU0345768153.USD","LU0130518102.USD","LU0061475181.USD","GOOY","LU0345768740.USD","METV","SNPE","HK0000532082.HKD","AVGG","LU0994945656.USD","LU1429558221.USD","LU2108987350.USD","SG9999015952.SGD","DARP","AVS","LU0234572021.USD","LU1074936037.SGD","LU0557290698.USD","LU2236285917.USD","LU0348723411.USD","LU1430594728.SGD","LU1069347547.HKD","IE00BMPRXR70.SGD","LU1003077747.HKD","LU2265009873.SGD","LU0149725797.USD","MQQQ","AMZD","LU0096364046.USD","IE00BMPRXQ63.HKD","LU2125909247.SGD","LU1699723380.USD","IE00BLSP4452.SGD","LU2637965513.SGD","LU1979441026.SGD","ORCU","BK4077","AXTL","LU0545039389.USD","GPTY","LU0949170426.SGD","LU0433182093.SGD","LU2381873111.SGD","BK4543","BK4534","LU1201861165.SGD","IE00BJTD4N35.SGD","BK4598","SG9999001077.SGD","USMD","LU1988902786.USD","IE00BFMHRM44.USD","LU1934455277.USD","SKYY","SMCL","LU0289960550.SGD","LU0868494708.USD","LU2237438978.USD","THMZ","XLC","LU2360032135.SGD","LU2023251221.USD","SGXZ80539844.SGD","LU1084165304.USD","TTEQ","IE00BDCRKT87.USD","IE00BZ199S13.USD","LU1280957306.USD","LU0057025933.USD","LU1244550494.USD","LU0787776722.HKD","LU1366333091.USD","BK4507","GGLL","GOOG","LU0353189680.USD","SMCY","AMZO","LU0225283273.USD","LU2764262908.HKD","LU0719512351.SGD","IE000BZT7R73.USD","LU2362541513.USD","IE0004445015.USD","LU1301847155.USD","LU0314104364.USD","CNEQ","LU0143551892.USD","LU0511384066.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589922","title":"Evotec initiates clinical trial evaluating JST-018","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666589922?lang=en_us&edition=fundamental","pubTime":"2026-09-09 17:15","pubTimestamp":1788945324,"startTime":"0","endTime":"0","summary":"Evotec (EVO) announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evotec-initiates-clinical-trial-evaluating-jst-018-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evotec-initiates-clinical-trial-evaluating-jst-018-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","GDOC","IDNA","BK4121","NVIB","MEDX","EVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","XPH","BME","IDNA","MEDX","WDNA","PJP","BBP","GNOM","FHLC","IBBJ","PBPH","BIB","JDOC","CURE","TBXU","PINK","IEIH","FTXH","MEDI","CANC","LFSC","HYLG","PTH","AZNH","CNCR","GNMX","GPCR","GSKH","IBBQ","PSCH","FXH","APXH","MNTL","MRNY","BBH","PSIL","LLYX","MDTX","NVIB","GDOC","JHMH","HRTS","PBE","RSPH","FBT","SBIO","SYNB","SURI","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665730023","title":"Medicus Pharma Sharpened Strategy Centers on Precision Oncology and Targeted Rare Disease Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665730023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665730023?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:11","pubTimestamp":1788873063,"startTime":"0","endTime":"0","summary":"An announcement from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma has repositioned itself as a precision oncology-led biotech, m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-sharpened-strategy-centers-on-precision-oncology-and-targeted-rare-disease-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-sharpened-strategy-centers-on-precision-oncology-and-targeted-rare-disease-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNCR","MDCX","XBIX","BK4139","CANC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HRTS","FHLC","BME","FTXH","PJP","BIB","TBXU","PSCH","GSKH","CANC","AZNH","IBB","GNOM","NVIB","IBBQ","WDNA","FXH","PBE","CNCR","PBPH","PTH","LENZ","APXH","SBIO","LLYX","BBH","IDNA","CURE","GPCR","PINK","SURI","LFSC","JHMH","MEDX","IBBJ","XPH","SYNB","PSIL","MRNY","FBT","MDTX","MEDI","MNTL","JDOC","IBRN","HYLG","GNMX","BBP","RSPH","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321700","title":"Ascletis Starts U.S. Phase I Trial of Oral Obesity Drug ASC36","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321700?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:08","pubTimestamp":1788862087,"startTime":"0","endTime":"0","summary":"Ascletis Pharma, Inc. ( ($HK:1672) ) has issued an announcement. Ascletis Pharma Inc. has initiated a Phase I clinical trial in the U.S. for ASC36 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascletis-starts-u-s-phase-i-trial-of-oral-obesity-drug-asc36?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascletis-starts-u-s-phase-i-trial-of-oral-obesity-drug-asc36?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","IDNA","GDOC","NVIB","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665703321","title":"Roivant Sciences announces ‘positive’ results from Phase 2 PHocus clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665703321","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665703321?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:05","pubTimestamp":1788861944,"startTime":"0","endTime":"0","summary":"Roivant announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-announces-positive-results-from-phase-2-phocus-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-announces-positive-results-from-phase-2-phocus-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","HYLG","NVIB","IDNA","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665601324","title":"MediciNova to Participate in Two Investor Conferences in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2665601324","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665601324?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":"LA JOLLA, Calif., Sept.  08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchang","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357430/7767/en/medicinova-to-participate-in-two-investor-conferences-in-september.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1548497426.USD","LU0006306889.USD","BK4127","LU2347655156.SGD","LU1720051108.HKD","LU2111349929.HKD","HYLG","LU0528227936.USD","LU2264538146.SGD","BK4588","BK4139","LU2028103732.USD","KBWB","BK4504","BK4585","LU1989772840.SGD","IE00BZ1G4Q59.USD","LU0971096721.USD","LU0053666078.USD","BK4516","IE00BKVL7J92.USD","GDOC","LU0557290698.USD","LU1074936037.SGD","LU1720051017.SGD","LU0795875169.SGD","MNOV","LU2089284900.SGD","BK4534","LU0912757837.SGD","LU0098860793.USD","LU1732799900.SGD","LU1989772923.USD","LU2133065610.SGD","IAI","LU0390134368.USD","BMED","IE00B3S45H60.SGD","NVIB","MEDX","LU2487616109.SGD","LU1064131342.USD","LU1791710400.SGD","LU1791710582.SGD","IDNA","LU0210528500.USD","LU0267386448.USD","LU0234570918.USD","LU2089283258.USD","LU0106831901.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":170,"code":"91000000","status":"200"}]}}